Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9807815 | 0.83 | USP2 (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL24170112 | 0.80 | PRKCA (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL6765372 | 0.80 | PRKCA (0.45) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL5460546 | 0.80 | PRKCA (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL4604786 | 0.79 | LMNA (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL2673586 | 0.79 | LMNA (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL27577094 | 0.79 | KDM4E (0.47) | LMNAOR51E2SMN1; SMN2TET2TET3 | |
| SCHEMBL1774725 | 0.79 | SMN1; SMN2 (0.33) | USP2SLCO1B1SMN1; SMN2TET2TET3 | |
| SCHEMBL8082885 | 0.79 | LMNA (0.48) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL8089557 | 0.79 | LMNA (0.48) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627176-B2 | Therapy; diagnosis | PROCTER & GAMBLE COMPANY | 2003-09-30 | — | — | US | disclosed |
| US-20020041846-A1 | Metal complexes for use in medical and therapeutic applications | PROCTER & GAMBLE COMPANY, THE | 2002-04-11 | — | — | US | disclosed |
| US-6056939-A | Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals | BRACCO IMAGING S.P.A. (IT) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041846-A1 | Metal complexes for use in medical and therapeutic applications | SLC8B1, LETM1, SLC30A5 | PDE4A 4883/4885USP2 4847/4885SLCO1B1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.